Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Semaglutide to Zenagamtide

NCT07855133 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07855133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07855133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Semaglutide to Zenagamtide
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 6, 2028
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight, type 2 diabetes